The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.
The COVID-19 pandemic and ANCA-associated vasculitis - reports from the EUVAS meeting and EUVAS education forum.
复制标题
DOI：
10.1016/j.autrev.2021.102986
复制
发表时间：
2021-12
影响因子：
13.6
通讯作者：
Jayne DRW
中科院分区：
文献类型：
--
作者：
Kronbichler A;Geetha D;Smith RM;Egan AC;Bajema IM;Schönermarck U;Mahr A;Anders HJ;Bruchfeld A;Cid MC;Jayne DRW
2019年冠状病毒病(新冠肺炎)大流行影响了抗中性粒细胞胞浆抗体(ANCA)相关性小血管炎患者的治疗。关于新冠肺炎后脉管炎患者预后的数据很少，但死亡率高于一般人群，与接受血液透析或肾移植的患者相当(报道的死亡率为20-25%)。据报道，诊断延误与透析依赖等后遗症有关。ANCA相关性脉管炎的治疗没有改变，目的是抑制疾病活动和减轻疾病负担。利妥昔单抗是一种重要和广泛使用的药物，它的使用与新冠肺炎更严重的住院病程以及严重急性呼吸综合征-CoV-2感染后缺乏抗体有关，这容易使患者再次感染。目前关于疫苗抗体反应的报道很少，但初步发现免疫反应受损，特别是当患者接受利妥昔单抗治疗时。在前六个月内使用利妥昔单抗的患者中，报告的血清阳性率不到20%，抗体反应与CD19+B细胞重新繁殖相关。如果疾病活动允许，建议使用CD19+B细胞引导策略推迟维持量。用于ANCA相关性脉管炎的其他免疫抑制措施也会削弱体液和细胞疫苗反应。定期测量疫苗反应或采取基于时间的医疗保健政策策略可提供额外剂量(“助推器”)的新冠肺炎疫苗。这篇综述总结了欧洲脉管炎协会最近的一个教育论坛和最近的一个虚拟会议，重点是新冠肺炎。
The Coronavirus Disease 2019 (COVID-19) pandemic influenced the management of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. A paucity of data exists on outcome of patients with vasculitis following COVID-19, but mortality is higher than in the general population and comparable to patients undergoing haemodialysis or kidney transplant recipients (reported mortality rates of 20–25%). Delays in diagnosis have been reported, which are associated with sequelae such as dialysis-dependency. Management of ANCA-associated vasculitis has not changed with the aim to suppress disease activity and reduce burden of disease. The use of rituximab, an important and widely used agent, is associated with a more severe hospital course of COVID-19 and absence of antibodies following severe acute respiratory syndrome (SARS)-CoV-2 infections, which prone patients to re-infection. Reports on vaccine antibody response are scarce at the moment, but preliminary findings point towards an impaired immune response, especially when patients receive rituximab as part of their treatment. Seropositivity was reported in less than 20% of patients when rituximab was administered within the prior six months, and the antibody response correlated with CD19+ B-cell repopulation. A delay in maintenance doses, if disease activity allows, has been suggested using a CD19+ B-cell guided strategy. Other immunosuppressive measures, which are used in ANCA-associated vasculitis, also impair humoral and cellular vaccine responses. Regular measurements of vaccine response or a healthcare-policy time-based strategy are indicated to provide additional doses (“booster”) of COVID-19 vaccines. This review summarizes a recent educational forum and a recent virtual meeting of the European Vasculitis Society (EUVAS) focusing on COVID-19.
登录
查看更多内容
DOI：
10.1093/ndt/gfab174
发表时间：
2021-08-27
期刊：
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
影响因子：
--
作者：
Bruchfeld A;Kronbichler A;Alberici F;Fervenza FC;Jayne DRW;Segelmark M;Tesar V;Szpirt WM
通讯作者：
Szpirt WM
免疫介导的用利妥昔单抗治疗的免疫介导的肾脏疾病患者对BNT162B2 SARS-COV-2疫苗接种的体液反应率低。
影响因子：
4.6
作者：
Demoulin N;Scohy A;Gillion V;Godefroid N;Jadoul M;Morelle J
通讯作者：
Morelle J
影响因子：
27.4
作者：
Bijlsma JW
通讯作者：
Bijlsma JW
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group
影响因子：
64.8
作者：
Carvelli, Julien;Demaria, Olivier;Vivier, Eric
通讯作者：
Vivier, Eric